China approves Hengrui breast cancer drug on Phase II data

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer

Read the full 263 word article

How to gain access

Continue reading with a
two-week free trial.